Cardioarginine

Cardioarginine is a metabolic drug with endothelial and cardioprotective effects, as well as an adaptogenic and hypotensive effect.

The drug helps to reduce myocardial ischemia, improves coronary blood flow, stabilizes the endothelium of peripheral and coronary vessels, and also demonstrates membrane-stabilizing, antiradical, antihypoxic and antioxidant activity. [ 1 ]

In case of increased blood pressure values, the drug helps to stabilize the pressure and reduces the systemic resistance exerted by peripheral vessels. [ 2 ]

Indications Cardioarginine

It is used for the combined treatment of CHF and coronary heart disease (a stable type of angina associated with vascular spasm or dysfunction, as well as painless myocardial ischemia), as well as atherosclerosis in the brain and heart vessels, hypercholesterolemia, diabetic angiopathy and low blood pressure.

In addition, it is prescribed at an early stage of the recovery period after myocardial infarction and other somatic pathologies.

It can be used in case of heart rhythm disorders associated with a deficiency of Mg and K in the body (mainly in case of ventricular arrhythmias), and also when using SG and in obliterating endarteritis.

Release form

The drug is released in the form of injection liquid - inside ampoules with a capacity of 5 ml. The pack contains 5 or 10 such ampoules.

Pharmacodynamics

The hypotensive effect of the drug develops with the participation of arginine, which, being a donor of nitrous oxide, can potentiate endothelium-dependent vasodilation, and in addition, regulates blood pressure and maintains the osmolarity of fluids within the body and the amount of blood, joining the binding of arginine vasopressin (peptidergic hormone).

The cardioprotective metabolic effect of the drug is due to the fact that arginine, succinate and aspartate are able to activate the energy supply of the heart muscle, restore the potential of cellular energy and stabilize the intermediate metabolism with acid-base indicators; in addition, these substances stabilize protein metabolism inside the myocardium and stimulate the binding of aminosaccharin with amino acids and nucleotides. [ 3 ]

Asparaginate is an intracellular transporter of K+ and Mg2+ ions. Its activity helps eliminate salt imbalance and improve coronary blood flow. Mg2+ ions help activate the activity of Na+-K+-ATPase, which lowers the level of Na+ ions inside cells and increases the intensity of K+ ion passage. A decrease in intracellular Na+ ion values slows down the metabolism of these elements with the formation of Ca2+ ions inside the smooth vascular muscles, causing them to relax. K+ ions help activate the binding of glycogen to acetylcholine, ATP and proteins.

Cardioarginine has adaptogenic-actoprotective activity, inducing cellular metabolism through substrates. Succinate with arginine and asparaginate stimulate enzymatic processes of the TCA cycle and cellular destruction of glucose with fatty acids during physical exertion. In addition, they have a positive effect on aerobic cellular energy supply and reduce lactic acidosis.

The effects described above help to increase the rate of adaptation to hypoxia, reduce severe fatigue and increase work capacity.

Dosing and administration

The medication is administered intravenously - by jet or through a drip.

When using a dropper, 5 ml of the substance is administered intravenously 1-2 times a day, diluted in 5% glucose or 0.9% NaCl (0.1-0.2 l). The rate of administration is 20-30 drops/minute.

Using the jet method, the drug in a dosage of 5 ml is administered at a low speed (maximum 5 ml per minute) 1-2 times per day.

The therapy lasts for 5-10 days. No more than 10 ml of the drug can be administered per day.

After completing the cycle of intravenous injections, the patient, if necessary, can be transferred to the use of Cardioarginine in the form of syrup for oral administration.

• Application for children

There is no information regarding the therapeutic efficacy and safety of drug use in pediatrics.

Use Cardioarginine during pregnancy

There is no information regarding the drug's safety during pregnancy, so it is not used during this period.

You should not breastfeed while using this medicine.

Contraindications

Main contraindications:

• pronounced personal sensitivity to the components of the drug;
• hyperkalemia;
• AV block stage 1-2.

Side effects Cardioarginine

Side effects include:

• problems with digestive function: nausea, stomach pain and mild discomfort inside the gastrointestinal tract, diarrhea, vomiting, bloating, bleeding and ulcers inside the gastrointestinal tract, dyspeptic symptoms and thirst immediately after taking the drug, which go away on their own, are occasionally observed;
• disorders of the cardiovascular system: conduction disorders within the ventricles of the heart and a decrease in blood pressure;
• disorders of the nervous system: fever, dizziness, convulsions, muscle weakness, disorientation and facial hyperemia, as well as hyporeflexia, paresthesia, hyperhidrosis and respiratory depression;
• epidermal lesions: signs of an allergic reaction (itching) may appear;
• Others: asthenia, dyspnea, venous thrombosis, myasthenia and phlebitis.

In case of high intravenous injection rate, muscle hypotonia, arrhythmia, hyperkalemia or -magnesemia, paresthesia in the extremities, inhibition of AV conduction and cardiac arrest may be observed.

Overdose

In poisoning, stomach pain, paresthesia, hyperkalemia or -magnesemia, metallic taste and muscle stiffness appear, and blood pressure decreases. In addition, the ECG shows an increase in the amplitude of the T-wave and a decrease in the amplitude of the P-wave, as well as an increase in the size of the QRS complex.

Symptomatic measures are taken to support the functioning of vital organs, and Ca substances are administered parenterally.

Interactions with other drugs

It is necessary to take into account that in the case of a combination of arginine and aminophylline, an increase in the blood level of insulin is observed; when using the substance together with spironolactone, the blood level of potassium increases.

The medication increases the tolerance of SG and also potentiates the activity of drugs that stimulate myocardial trophism.

Cardioarginine prevents the occurrence of hypokalemia associated with the administration of glycemic control, saluretics and corticosteroids.

Combination with ACE inhibitors or potassium-sparing diuretics increases the likelihood of hyperkalemia (plasma potassium levels should be monitored).

The drug reduces the body's sensitivity to SG.

Storage conditions

Cardioarginine should be stored in a place closed to small children. Do not freeze ampoules with the solution. Temperature level is maximum 25°C.

Shelf life

Cardioarginine can be used within a 3-year period from the date of manufacture of the pharmaceutical component.

Analogues

Analogues of the drug are the substances Cardiolin, Thiodaron and Advokard with A-dyston, Korargin and Distonin with Alvisan, and also Cardiophyte and Validazole. In addition, the list includes Kratal with Zelenin drops, Homviocorin and Validol with Cor compositum, Trikardin and Corvalment.